MedImmune drops Synagis partner, plans to hire 125
MedImmune has dropped Abbott Labs from a co-marketing deal for Synagis, a therapy for respiratory infections in infants, and will beef up its sales force by 125. The Gaithersburg, Maryland-based biotech says that the move should add significantly to earnings in 2007. MedImmune has been focusing a growing amount of its attention on pediatric drugs.
- read this report from the Washington Business Journal for more
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
